“Alpha-Synuclein Antibodies and Uses Thereof.” 1. https://patents.google.com/patent/WO2014132210A1/en#patentCitations (September 22, 2024).

“BioArctic Receives Patent in Japan for New Antibodies Targeting Parkinson’s Disease.” 4. https://www.prnewswire.com/news-releases/bioarctic-receives-patent-in-japan-for-new-antibodies-targeting-parkinsons-disease-301907860.html (September 22, 2024).

Aho VTE, Houser MC, Pereira PAB, Chang J, Rudi K, Paulin L et al (2021) Relationships of gut microbiota, short-chain fatty acids, inflammation, and the gut barrier in Parkinson’s disease. Mol Neurodegener 16(1):1–14. https://doi.org/10.1186/s13024-021-00427-6

Article  CAS  Google Scholar 

Akhter N, Bin Wu, Memon AM, Mohsin M (2015) Probiotics and prebiotics associated with aquaculture: a review. Fish Shellfish Immunol 45(2):733–741. https://doi.org/10.1016/j.fsi.2015.05.038

Article  CAS  PubMed  Google Scholar 

Anna O, Oniszczuk T, Gancarz M, Nska JS, Hamaguchi M (2021) Molecules role of gut microbiota, probiotics and prebiotics in the cardiovascular diseases. Molecules 2021(26):1172. https://doi.org/10.3390/molecules26

Article  Google Scholar 

Aroniadis OC, Brandt LJ (2013) Fecal microbiota transplantation. Curr Opin Gastroen 29(1):79–84. https://doi.org/10.1097/MOG.0b013e32835a4b3e

Article  Google Scholar 

Ayten Ş, Bilici S (2024) Modulation of gut microbiota through dietary intervention in neuroinflammation and Alzheimer’s and Parkinson’s Diseases. Curr Nutr Rep 13(2):82–96. https://doi.org/10.1007/s13668-024-00539-7

Article  PubMed  PubMed Central  Google Scholar 

Bhidayasiri R, Sringean J, Phumphid S, Anan C, Thanawattano C, Deoisres S et al (2024) The rise of Parkinson’s disease is a global challenge, but efforts to tackle this must begin at a national level: a protocol for national digital screening and “eat, move, sleep” lifestyle interventions to prevent or slow the rise of non-communicable diseases in Thailand. Front Neurol 15:1386608

Article  PubMed  PubMed Central  Google Scholar 

Bicknell B, Liebert A, McLachlan CS, Kiat H (2022) Microbiome changes in humans with Parkinson’s Disease after photobiomodulation therapy: a retrospective study. J Pers Med 12(1):49. https://doi.org/10.3390/jpm12010049

Article  PubMed  PubMed Central  Google Scholar 

Bicknell B, Liebert A, Herkes G (2024) Parkinson’s disease and photobiomodulation: potential for treatment. J Pers Med 14(1):112. https://doi.org/10.3390/jpm14010112

Article  PubMed  PubMed Central  Google Scholar 

Binda S, Tremblay A, Iqbal UH, Kassem O, Le Barz M, Thomas V, Bronner S et al (2024) Psychobiotics and the microbiota–gut–brain axis: where do we go from here? Microorganisms 12(4):634. https://doi.org/10.3390/microorganisms12040634

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bucur M, Papagno C (2023) Deep brain stimulation in Parkinson’s Disease: a meta-analysis of the long-term neuropsychological outcomes. Neuropsychol Rev 33(2):307–346. https://doi.org/10.1007/s11065-022-09540-9

Article  PubMed  Google Scholar 

Carbone F, Djamshidian A, Seppi K, Poewe W (2019) Apomorphine for Parkinson’s Disease: efficacy and safety of current and new formulations. CNS Drugs 33(9):905–918. https://doi.org/10.1007/s40263-019-00661-z

Article  PubMed  PubMed Central  Google Scholar 

Çınar E, Tel BC, Şahin G (2022) Neuroinflammation in Parkinson"s Disease and its treatment opportunities. Balkan Med J 39(5):318–333. https://doi.org/10.4274/balkanmedj.galenos.2022.2022-7-100

Article  CAS  PubMed  PubMed Central  Google Scholar 

Contin M, Riva R, Albani F, Baruzzi A (1996) Pharmacokinetic optimisation in the treatment of Parkinson’s Disease. Clin Pharmacokinet 30(6):463–481. https://doi.org/10.2165/00003088-199630060-00004

Article  CAS  PubMed  Google Scholar 

Dias V, Junn E, Maral Mouradian M (2013) The role of oxidative stress in Parkinson’s Disease. JPD 3(4):461–491. https://doi.org/10.3233/JPD-130230

Article  CAS  PubMed  Google Scholar 

Dinan TG, Stanton C, Cryan JF (2013) Psychobiotics: a novel class of psychotropic. Biol Psychiatry 74(10):720–726. https://doi.org/10.1016/j.biopsych.2013.05.001

Article  CAS  PubMed  Google Scholar 

Duperrier S, Bortolozzi A, Sgambato V (2022) Increased expression of alpha, beta-, and gamma-synucleins in brainstem regions of a non-human primate model of Parkinson’s Disease. Int J Mol Sci 23(15):8586. https://doi.org/10.3390/ijms23158586

Article  CAS  PubMed  PubMed Central  Google Scholar 

Enright BP, Huang Y, Kym PR, Lao Y, Lou X, Mackey SE, Mayer PT, Miller CP, Stella VJ, Voight EA, Inventors; AbbVie Inc, Assignee. Methods of Treating Parkinson’s Disease. United States Patent US 11,091,507. 2021.” https://patents.google.com/patent/US11091507B2/en (September 22, 2024).

Esha P, Das L, Das AK, Dolui S, Saha S, Pal U, Mondal A et al (2023) Single point mutations at the S129 residue of α-synuclein and their effect on structure, aggregation, and neurotoxicity. FCHEM 11:1145877. https://doi.org/10.3389/fchem.2023.1145877

Article  CAS  Google Scholar 

Farias D, de Paulo F, de Araújo F, Neri-Numa IA, Pastore GM (2019) Prebiotics: trends in food, health and technological applications. Trends Food Sci Technol 93:23–35. https://doi.org/10.1016/j.tifs.2019.09.004

Article  CAS  Google Scholar 

“Fariello R, Cattaneo C, Salvati P, Benatti L, Inventors; Newron Pharmaceuticals SpA, Assignee. Methods for Treatment of Parkinson’s Disease. United States Patent US 8,283,380. 2012 Oct 9.” https://patents.google.com/patent/US8283380B2/en (September 22, 2024).

Hey G, Nair N, Klann E, Gurrala A, Safarpour D, Mai V, RamirezZamora A, Vedam-Mai V (2023) Therapies for Parkinson’s Disease and the gut microbiome: evidence for bidirectional connection. Front Aging Neurosci 15:1151850. https://doi.org/10.3389/fnagi.2023.1151850

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hong N (2019) Photobiomodulation as a treatment for neurodegenerative disorders: current and future trends. Biomed Eng Lett 9(3):359–366. https://doi.org/10.1007/s13534019-00115-x

Article  PubMed  PubMed Central  Google Scholar 

Jenner P (2003) Oxidative stress in Parkinson’s Disease. Ann Neurol 53(S3):S26-38. https://doi.org/10.1002/ana.10483

Article  CAS  PubMed  Google Scholar 

Jensen PH, Hojrup P, Hager H, Nielsen MS, Jacobsen L, Olesen OF, Gliemann J, Jakes R (1997) Binding of Abeta to alpha- and beta-synucleins: identification of segments in alpha-synuclein/NAC precursor that bind Abeta and NAC. Biochem J 323:539–546. https://doi.org/10.1042/bj3230539

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jing L, Fei Xu, Nie Z, Shao L (2020a) Gut microbiota approach—a new strategy to treat Parkinson’s Disease. Front Cell Infect Microbiol 10:570658. https://doi.org/10.3389/fcimb.2020.570658

Article  CAS  Google Scholar 

Jonathan T, Nitu B, Datieva V, Odin P, Antonini A (2017) DeviceAided treatment strategies in advanced Parkinson’s Disease. Int Rev Neurobiol 132:453–474. https://doi.org/10.1016/bs.irn.2017.03.001

Article  CAS  Google Scholar 

Kim DJ, Isidro-Pérez AL, Doering M, Llibre-Rodriguez JJ, Acosta I, Rodriguez AM et al (2023) Prevalence and incidence of Parkinson’s Disease in Latin America: a meta-analysis. Mov Disord. https://doi.org/10.1002/mds.29682

Article  PubMed  PubMed Central  Google Scholar 

Ķimse L, Reinis A, Miķelsone-Jansone L, Gintere S, Krūmiņa A (2024a) A narrative review of psychobiotics: probiotics that influence the gut-brain axis. Med Tradic 60(4):601. https://doi.org/10.3390/medicina60040601

Article  Google Scholar 

Ķimse L, Reinis A, Miķelsone-Jansone L, Gintere S, Krūmiņa A (2024b) A narrative review of psychobiotics: probiotics that influence the gut-brain axis. Med 60(4):601. https://doi.org/10.3390/medicina60040601

Article  Google Scholar 

Lashuel HA, Overk CR, Oueslati A, Masliah E (2013) The many faces of α-synuclein: from structure and toxicity to therapeutic target. Nat Rev Neurosci 14:38–48. https://doi.org/10.1038/nrn3406

Article  CAS  Google Scholar 

Latif K, Aman U, Anastasiia DS, Dmytro IB, Zakia R, Badrah SA, Mohamed AA, Ghulam MA (2022) Drug reprofiling history and potential th